SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0000950170-23-062918
Filing Date
2023-11-13
Accepted
2023-11-13 16:05:28
Documents
13
Period of Report
2023-11-13
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K kzr-20231113.htm   iXBRL 8-K 48046
2 EX-99.1 kzr-ex99_1.htm EX-99.1 122141
  Complete submission text file 0000950170-23-062918.txt   298586

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT kzr-20231113.xsd EX-101.SCH 2493
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT kzr-20231113_lab.xml EX-101.LAB 13350
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT kzr-20231113_pre.xml EX-101.PRE 9857
7 EXTRACTED XBRL INSTANCE DOCUMENT kzr-20231113_htm.xml XML 4713
Mailing Address 4000 SHORELINE COURT, SUITE 300 SOUTH SAN FRANCISCO CA 94080
Business Address 4000 SHORELINE COURT, SUITE 300 SOUTH SAN FRANCISCO CA 94080 650-822-5600
Kezar Life Sciences, Inc. (Filer) CIK: 0001645666 (see all company filings)

IRS No.: 473366145 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38542 | Film No.: 231398569
SIC: 2834 Pharmaceutical Preparations